Noxopharm (ASX:NOX)

Executive Summary

Noxopharm Limited (ASX:NOX) is a clinical-stage Australian biotechnology company developing novel therapies for oncology and immunology based on its proprietary Sofra™ and Chroma™ platforms. The Sofra™ platform targets mRNA vaccine safety and autoimmune/inflammatory diseases, while Chroma™ drives oncology drug discovery. The company's lead candidate, Veyonda®, is currently in a Phase 1 trial for cancer in combination with immunotherapy, evaluating safety and early efficacy. Noxopharm's dual-platform strategy positions it to address significant unmet needs in both cancer and immune-mediated disorders. As a public company with a market capitalization reflecting early-stage risk, Noxopharm's near-term value hinges on successful execution of its clinical and preclinical programs. The company operates out of Sydney, Australia, with a team of 50-200 employees.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 Veyonda + immunotherapy interim safety/efficacy data40% success
• H2 2026Preclinical proof-of-concept data for Chroma platform oncology candidate50% success